{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:25:24Z","timestamp":1793715924820,"version":"4.6.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003482","name":"Hebei Province Department of Education","doi-asserted-by":"publisher","award":["20260636"],"award-info":[{"award-number":["20260636"]}],"id":[{"id":"10.13039\/501100003482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471022"],"award-info":[{"award-number":["81471022"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009964","name":"Tangshan Science and Technology Bureau","doi-asserted-by":"publisher","award":["25150212E"],"award-info":[{"award-number":["25150212E"]}],"id":[{"id":"10.13039\/501100009964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008238","name":"Hebei Provincial Department of Science And Technology","doi-asserted-by":"publisher","award":["H2022209087"],"award-info":[{"award-number":["H2022209087"]}],"id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lfs.2026.124534","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:44:09Z","timestamp":1782283449000},"page":"124534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Inflammation-mediated diabetes-liver disease cross-organ crosstalk: From molecular mechanisms to precision therapeutic strategies"],"prefix":"10.1016","volume":"402","author":[{"given":"Yue","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2026.124534_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25168731","article-title":"Pathophysiological relationship between type 2 diabetes mellitus and metabolic dysfunction-associated Steatotic liver disease: novel therapeutic approaches","volume":"25","author":"Ferdous","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124534_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111652","article-title":"Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population","volume":"211","author":"Chew","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2026.124534_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112918","article-title":"Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM","volume":"229","author":"Wu","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2026.124534_bb0020","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s40618-025-02621-5","article-title":"The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction","volume":"48","author":"Herrera-Ojeda","year":"2025","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.lfs.2026.124534_bb0025","article-title":"Feeding-induced hepatokines and crosstalk with multi-organ: A novel therapeutic target for type 2 diabetes","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.lfs.2026.124534_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.lfs.2026.124534_bb0035","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41423-025-01307-5","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume":"22","author":"He","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.lfs.2026.124534_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109395","article-title":"Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE)","volume":"253","author":"Gonz\u00e1lez-Mendoza","year":"2025","journal-title":"Thromb. Res."},{"key":"10.1016\/j.lfs.2026.124534_bb0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic Steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2026.124534_bb0050","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3389\/fimmu.2020.01582","article-title":"The effects of type 2 diabetes mellitus on organ metabolism and the immune system","volume":"11","author":"Daryabor","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124534_bb0055","article-title":"Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","author":"Qi","year":"2024","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.lfs.2026.124534_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12933-025-02707-7","article-title":"Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF","volume":"24","author":"Luo","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.lfs.2026.124534_bb0065","doi-asserted-by":"crossref","first-page":"780","DOI":"10.5604\/16652681.1171746","article-title":"The treatment of diabetes mellitus of patients with chronic liver disease","volume":"14","author":"Garc\u00eda-Compe\u00e1n","year":"2015","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.lfs.2026.124534_bb0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/MOG.0000000000001083","article-title":"Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot","volume":"41","author":"Kaya","year":"2025","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.lfs.2026.124534_bb0075","article-title":"Macrophages, chronic inflammation, and insulin resistance","volume":"11","author":"Li","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2026.124534_bb0080","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nm1166","article-title":"Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB","volume":"11","author":"Cai","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2026.124534_bb0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/1744666X.2023.2294046","article-title":"The pathophysiology of MASLD: an immunometabolic perspective","volume":"20","author":"Schw\u00e4rzler","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.lfs.2026.124534_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26199715","article-title":"Obesity-driven metabolic disorders: the interplay of inflammation and mitochondrial dysfunction","volume":"26","author":"Choi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124534_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2026.124534_bb0100","article-title":"Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure","author":"Yu","year":"2025","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.lfs.2026.124534_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1530\/JOE-18-0078","article-title":"Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD","volume":"237","author":"Patton","year":"2018","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.lfs.2026.124534_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1620585","article-title":"Inflammation: a key mechanism connecting metabolic-associated steatotic liver disease and systemic arterial hypertension","volume":"16","author":"Solleiro-Villavicencio","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124534_bb0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/1873-3468.14313","article-title":"Mechanisms of interorgan crosstalk in health and disease","volume":"596","author":"Herrlich","year":"2022","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lfs.2026.124534_bb0120","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2337\/db25-0979","article-title":"Adipose tissue resistance to the Antilipolytic effect of insulin and niacin in humans with obesity","volume":"75","author":"Lin","year":"2026","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2026.124534_bb0125","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCRESAHA.125.325593","article-title":"Modulating the Secretome of fat to treat heart failure","volume":"136","author":"Salyer","year":"2025","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2026.124534_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910795","article-title":"Hepatokines and MASLD: the GLP1-Ras-FGF21-Fetuin-A crosstalk as a therapeutic target","volume":"25","author":"Milani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124534_bb0135","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1016\/j.apsb.2025.08.028","article-title":"Intestinal barrier in chronic gut and liver diseases: pathogenesis and therapeutic targets","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.lfs.2026.124534_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms14020471","article-title":"The gut-liver Axis in MASLD: from host-microbiome crosstalk to precision therapeutics","volume":"14","author":"Zhou","year":"2026","journal-title":"Microorganisms"},{"key":"10.1016\/j.lfs.2026.124534_bb0145","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease","volume":"82","author":"Fuchs","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.lfs.2026.124534_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/biology11111622","article-title":"Gut-liver Axis and non-alcoholic fatty liver disease: A vicious circle of dysfunctions orchestrated by the gut microbiome","volume":"11","author":"Pezzino","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.lfs.2026.124534_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.lfs.2026.124534_bb0160","article-title":"Polymerized laminin-modified microcapsules improve pancreatic islet resilience towards cytokine induced inflammatory stress and lower chemoattractant cytokine secretion, materials today","volume":"32","author":"Silva","year":"2025","journal-title":"Bio"},{"key":"10.1016\/j.lfs.2026.124534_bb0165","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1111\/jdi.13654","article-title":"New mediators in diabetes pathogenesis: exosomes and metabolites","volume":"12","author":"Lee","year":"2021","journal-title":"Journal of diabetes investigation."},{"key":"10.1016\/j.lfs.2026.124534_bb0170","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCRESAHA.119.315687","article-title":"FOXP1: A gatekeeper of endothelial cell inflammation","volume":"125","author":"Kanter","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2026.124534_bb0175","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/ATVBAHA.124.319397","article-title":"Century of milestones and breakthroughs related to the immune mechanisms of atherosclerosis","volume":"44","author":"Mallat","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.lfs.2026.124534_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/nu18010012","article-title":"Dietary and behavioral strategies for weight loss and weight loss maintenance: A narrative review","volume":"18","author":"\u017burawski","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.lfs.2026.124534_bb0185","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","year":"2024","journal-title":"Obes. Facts"},{"key":"10.1016\/j.lfs.2026.124534_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41387-021-00152-5","article-title":"Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis","volume":"11","author":"Alssema","year":"2021","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.lfs.2026.124534_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15550-7","article-title":"The effects of the voglibose on non-alcoholic fatty liver disease in mice model","volume":"12","author":"Bae","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2026.124534_bb0200","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.lfs.2026.124534_bb0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/13813455.2021.1975758","article-title":"Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1\/TLR4\/NF-\u03baB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease","volume":"130","author":"Allam","year":"2024","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.lfs.2026.124534_bb0210","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(20)30381-8","article-title":"Management of diabetes and hyperglycaemia in the hospital","volume":"9","author":"Pasquel","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2026.124534_bb0215","first-page":"569","article-title":"Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus, nature reviews","volume":"15","author":"Foretz","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2026.124534_bb0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1060028020935105","article-title":"A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.lfs.2026.124534_bb0225","article-title":"Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.lfs.2026.124534_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: A Meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.lfs.2026.124534_bb0235","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2026.124534_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like Peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic Steatohepatitis: An updated Meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.lfs.2026.124534_bb0245","article-title":"Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases","author":"Kong","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124534_bb0250","first-page":"11","article-title":"Sodium-glucose Cotransporter-2 inhibitors in primary and secondary prevention of cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A Meta-analysis, the","volume":"70","author":"Kovil","year":"2022","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.lfs.2026.124534_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.108998","article-title":"Comparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis","volume":"39","author":"Liu","year":"2025","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.lfs.2026.124534_bb0260","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dom.16049","article-title":"Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study","volume":"27","author":"Lee","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2026.124534_bb0265","series-title":"Precision Medicine in Type 2 diAbetes: A Systematic Review of Treatment Effect Heterogeneity for GLP1-Receptor Agonists and SGLT2-Inhibitors, medRxiv: The Preprint Server for Health Sciences","author":"Young","year":"2023"},{"key":"10.1016\/j.lfs.2026.124534_bb0270","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/ncomms2608","article-title":"TRPM2 links oxidative stress to NLRP3 inflammasome activation","volume":"4","author":"Zhong","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124534_bb0275","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.lfs.2026.124534_bb0280","doi-asserted-by":"crossref","first-page":"8277","DOI":"10.2147\/JIR.S532908","article-title":"NLRP3 Inflammasome activation in liver disorders: from molecular pathways to therapeutic strategies","volume":"18","author":"Ma","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.lfs.2026.124534_bb0285","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1007\/s10753-023-01958-4","article-title":"METTL3 modulates TXNIP expression to affect the activation of NLRP3 Inflammasome in hepatic cells under oxygen-glucose deprivation\/reperfusion injury","volume":"47","author":"Zhang","year":"2024","journal-title":"Inflammation"},{"key":"10.1016\/j.lfs.2026.124534_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174884","article-title":"HM-chromanone attenuates TNF-\u03b1-mediated inflammation and insulin resistance by controlling JNK activation and NF-\u03baB pathway in 3T3-L1 adipocytes","volume":"921","author":"Park","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124534_bb0295","article-title":"Association between obesity, inflammation and insulin resistance: insights into signaling pathways and therapeutic interventions","volume":"200","author":"Garg","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2026.124534_bb0300","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13024-023-00666-9","article-title":"cGAS-STING triggers inflammaging-associated neurodegeneration","volume":"18","author":"Izquierdo","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.lfs.2026.124534_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.622262","article-title":"Metformin: A novel weapon against inflammation","volume":"12","author":"Bai","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124534_bb0310","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s12276-023-00998-y","article-title":"Where should siRNAs go: applicable organs for siRNA drugs","volume":"55","author":"Ahn","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lfs.2026.124534_bb0315","doi-asserted-by":"crossref","first-page":"735","DOI":"10.21037\/atm-20-5422","article-title":"Exosomes as therapeutic vehicles in liver diseases","volume":"9","author":"Ding","year":"2021","journal-title":"Annals of translational medicine."},{"key":"10.1016\/j.lfs.2026.124534_bb0320","first-page":"34","article-title":"MSC-exosomes as novel therapeutics in asthma and allergic airway inflammation","volume":"26","author":"Kurt","year":"2025","journal-title":"Thoracic research and practice."},{"key":"10.1016\/j.lfs.2026.124534_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101606","article-title":"Non-coding RNA-based regulation of inflammation","volume":"59","author":"Ashrafizadeh","year":"2022","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.lfs.2026.124534_bb0330","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1093\/nar\/gkz500","article-title":"mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway","volume":"47","author":"Liang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2026.124534_bb0335","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.yjmcc.2020.04.032","article-title":"Extracellular vesicular MicroRNA-27a* contributes to cardiac hypertrophy in chronic heart failure","volume":"143","author":"Tian","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.lfs.2026.124534_bb0340","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1136\/gutjnl-2023-331742","article-title":"RNA-based therapies in liver metabolic diseases","volume":"74","author":"Fontanellas","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.lfs.2026.124534_bb0345","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1186\/s40001-025-03073-6","article-title":"Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions","volume":"30","author":"Abdel-Rasol","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.lfs.2026.124534_bb0350","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1038\/s41467-023-40469-6","article-title":"mRNA 3\u2019UTR lengthening by alternative polyadenylation attenuates inflammatory responses and correlates with virulence of influenza A virus","volume":"14","author":"Bergant","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124534_bb0355","article-title":"MicroRNA-146b-5p suppresses pro-inflammatory mediator synthesis via targeting TRAF6, IRAK1, and RELA in lipopolysaccharide-stimulated human dental pulp cells","volume":"24","author":"Han","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124534_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1680878","article-title":"Macrophage-tregs crosstalk: the \u201chub\u201d of the immune network in MASLD","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124534_bb0365","first-page":"353","article-title":"Inhibition of pro-inflammatory cytokines by homalolide A and homalomenol A isolated from rhizomes of Homalomena pendula, Zeitschrift fur Naturforschung","volume":"80","author":"Nguyen","year":"2025","journal-title":"C, Journal of biosciences."},{"key":"10.1016\/j.lfs.2026.124534_bb0370","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.3350\/cmh.2024.0438","article-title":"Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease","volume":"31","author":"Caddeo","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.lfs.2026.124534_bb0375","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/HEP.0000000000000606","article-title":"RNA nanomedicine in liver diseases","volume":"81","author":"Bakrania","year":"2025","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.lfs.2026.124534_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15092276","article-title":"Exosomes: potential next-generation Nanocarriers for the therapy of inflammatory diseases","volume":"15","author":"Mori","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2026.124534_bb0385","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41423-025-01323-5","article-title":"The role of exosomes in immunopathology and potential therapeutic implications","volume":"22","author":"Wang","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.lfs.2026.124534_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2023.109499","article-title":"HIF1\u03b1\/miR-146\u03b1\/TRAF6\/NF-\u03baB axis modulates hepatic iron overload-induced inflammation","volume":"125","author":"Mo","year":"2024","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.lfs.2026.124534_bb0395","doi-asserted-by":"crossref","DOI":"10.1021\/acs.bioconjchem.3c00129","article-title":"Tumor-derived PD-L1+ exosomes with natural inflammation tropism for psoriasis-targeted treatment","author":"Jia","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.lfs.2026.124534_bb0400","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s40001-022-00792-y","article-title":"Exosome-mediated effects and applications in inflammatory diseases of the digestive system","volume":"27","author":"Wu","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.lfs.2026.124534_bb0405","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s13287-022-03010-y","article-title":"Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6\/STAT3 pathway in macrophages","volume":"13","author":"Tian","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.lfs.2026.124534_bb0410","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7150\/thno.73568","article-title":"Therapeutic delivery of microRNA-125a-5p oligonucleotides improves recovery from myocardial ischemia\/reperfusion injury in mice and swine","volume":"13","author":"Gao","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.lfs.2026.124534_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2019.105564","article-title":"Exosomes from adipose-derived mesenchymal stem cells ameliorate cardiac damage after myocardial infarction by activating S1P\/SK1\/S1PR1 signaling and promoting macrophage M2 polarization","volume":"114","author":"Deng","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.lfs.2026.124534_bb0420","article-title":"Bone marrow mesenchymal stem cell-derived exosomes ameliorate aging-induced btb impairment in porcine testes by activating autophagy and inhibiting ROS\/NLRP3 inflammasomes via the AMPK\/mTOR signaling pathway","volume":"vol. 13","author":"Zhou","year":"2024","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.lfs.2026.124534_bb0425","article-title":"Tumor Immunosenescence driven by chronic inflammation: mechanisms, microenvironment remodeling and therapeutic strategies","author":"Liu","year":"2025","journal-title":"Aging Dis."},{"key":"10.1016\/j.lfs.2026.124534_bb0430","article-title":"Regulation of the NLRP3 Inflammasome by post-translational modifications and small molecules","volume":"11","author":"Seok","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124534_bb0435","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.actbio.2024.06.014","article-title":"Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis","volume":"184","author":"Qin","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.lfs.2026.124534_bb0440","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/ATVBAHA.124.320686","article-title":"Multi-omics and single-cell omics: new tools in drug target discovery","volume":"44","author":"Loscalzo","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.lfs.2026.124534_bb0445","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.mayocp.2025.07.028","article-title":"Individualized medicine in the era of artificial intelligence","volume":"100","author":"Lazaridis","year":"2025","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lfs.2026.124534_bb0450","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1002\/1873-3468.70115","article-title":"From omics to AI-mapping the pathogenic pathways in type 2 diabetes","volume":"599","author":"O\u2019Sullivan","year":"2025","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lfs.2026.124534_bb0455","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-024-06306-1","article-title":"Targeting the NLRP3 inflammasome-IL-1\u03b2 pathway in type 2 diabetes and obesity","volume":"68","author":"Meier","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2026.124534_bb0460","article-title":"Development and validation of machine learning models for MASLD: based on multiple potential screening indicators","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.lfs.2026.124534_bb0465","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13098-024-01571-x","article-title":"Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus","volume":"17","author":"Hu","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.lfs.2026.124534_bb0470","article-title":"A consensus immune dysregulation framework for sepsis and critical illnesses","author":"Moore","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2026.124534_bb0475","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20231918","article-title":"Molecular regulation of NLRP3 inflammasome activation during parasitic infection","volume":"44","author":"Alonaizan","year":"2024","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.lfs.2026.124534_bb0480","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.inffus.2018.09.012","article-title":"Machine learning for integrating data in biology and medicine: principles","volume":"50","author":"Zitnik","year":"2019","journal-title":"Practice, and Opportunities, An international journal on information fusion."},{"key":"10.1016\/j.lfs.2026.124534_bb0485","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2026.124534_bb0490","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1186\/s12967-025-07075-0","article-title":"Macrophage polarization in diabetic vascular complications: mechanistic insights and therapeutic targets","volume":"23","author":"Cao","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2026.124534_bb0495","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1692742","article-title":"Metabolic crossroads in insulin resistance: exploring lipid dysregulation and inflammation","volume":"16","author":"Saadati","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124534_bb0500","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/0113895575361098250112085145","article-title":"Inflammation-driven Oncogenesis: precision medicine and immunotherapeutic strategies","volume":"25","author":"Alkaraki","year":"2025","journal-title":"Mini-Rev. Med. Chem."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526003437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526003437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:26:32Z","timestamp":1786479992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526003437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":100,"alternative-id":["S0024320526003437"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124534","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation-mediated diabetes-liver disease cross-organ crosstalk: From molecular mechanisms to precision therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124534"}}